Latest News

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual effects.

Twice-daily clobetasol 0.05% cleared cells in 26.5% vs 8.6% of patients and pain in 75.1% vs 32.4% after cataract surgery, with no added endothelial cell loss.

Initial phaco for angle-closure glaucoma climbed to 48.4% in adults 50 and older, while surveys and IRIS data show shifting trabeculectomy and JOAG surgical patterns.

A cataract expert discussed if postoperative topical antibiotics add protection after intracameral prophylaxis.

Oral PKC inhibitor darovasertib preserved the eye in 57% of patients facing enucleation and cut projected radiation doses in 70.3% in the phase 2 OptimUM-09 trial.

Noguchi FS formula error was 0.280 D in 486 eyes, LAL piggyback cut residual cylinder to 0.1 D, and Yamane and Gore-Tex fixation showed distinct complication profiles.

In the phase 3 RESTORE-3 trial of 116 Chinese participants, the anti-IGF-1R antibody produced a 60.4% proptosis response rate vs 23.5% with placebo at week 24.

The concerns of October 10, 1857, sound remarkably familiar today.

At the American Academy of Ophthalmology (AAO) 2026 Retina Subspecialty Day in New Orleans, Charles C. Wykoff, MD, PhD, presented 1-year primary end point results from the phase 3 DAYBREAK trial.

Stuart Therapeutics Inc. submitted an investigational NDA amendment to the FDA to study ST-100 (vezocolmitide) in corneal wound healing.

Michel Michaelides, MD, discusses phase 3 DRAGON results showing that oral tinlarebant slowed atrophic lesion growth by about 36% in adolescents with Stargardt disease.

A single intravitreal injection improved acuity in Stargardt disease; a randomized trial in geographic atrophy is planned.

Long-term data from the GLK-202-03 extension study show a sustained 1.9 D improvement in Kmax after a single epithelium-on cross-linking treatment, with no serious or treatment-related adverse events reported.